Wow.....
Terrible news for Edwards.
Global Healthcare Companies looking to enter the TAVR space must be smelling blood in the water as this market is ripe for disruption and the DurAVR offers precisely the most perfect and devastating technology to disrupt and TAKE this projected US$10 Billion+ market over, entirely.....
Boston Scientific, Johnson&Johnson and Abbott could all be very likely candidates to acquire AVR or the DurAVR in the future.
Update on Edwards, page-5
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
0.140(1.07%) |
Mkt cap ! $287.4M | |||
| Open | High | Low | Value | Volume |
| $13.33 | $13.91 | $13.23 | $264.5K | 19.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $13.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.34 | 469 | 4 |
View Market Depth
| Last trade - 13.16pm 13/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |